|Bid||29.00 x 1400|
|Ask||30.30 x 1400|
|Day's Range||29.67 - 30.27|
|52 Week Range||23.07 - 67.74|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2021 - Nov 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.55|
Subscribe to Yahoo Finance Plus to view Fair Value for BTAILearn more
Chasing short-term gains is usually not the best strategy in the stock market. Investing in solid companies and holding their shares for a long time is still the best way to grow your capital. However, some companies with a promising future can provide explosive short-term gains too.
Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell Neuroendocrine Prostate Cancer (SCNC) High unmet medical need with no FDA approved therapies for patients presenting with SCNC Data from the trial, including the expansion cohort, anticipated by Q1 2022 NEW HAVEN, Conn., Oct. 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stag
What happened Shares of BioXcel Therapeutics (NASDAQ: BTAI) were sinking 15.2% as of 11:25 a.m. EDT on Thursday. The decline came after the company's regulatory filing to the Securities and Exchange Commission revealed that chief commercial officer William P.